These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1043 related articles for article (PubMed ID: 20547242)

  • 21. Drug discovery through industry-academic partnerships.
    Gray NS
    Nat Chem Biol; 2006 Dec; 2(12):649-53. PubMed ID: 17108976
    [No Abstract]   [Full Text] [Related]  

  • 22. Re-formulating drugs and vaccines for intranasal delivery: maximum benefits for minimum risks?
    Watts PJ; Smith A
    Drug Discov Today; 2011 Jan; 16(1-2):4-7. PubMed ID: 21074635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transforming fragments into candidates: small becomes big in medicinal chemistry.
    de Kloe GE; Bailey D; Leurs R; de Esch IJ
    Drug Discov Today; 2009 Jul; 14(13-14):630-46. PubMed ID: 19443265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ask the experts: the challenges and benefits of flow chemistry to optimize drug development.
    Anderson N; Gernaey KV; Jamison TF; Kircher M; Wiles C; Leadbeater NE; Sandford G; Richardson P
    Future Med Chem; 2012 Sep; 4(14):1779-89. PubMed ID: 23043475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ADMET--Fifth Annual SMi Conference.
    Comer JE
    IDrugs; 2010 Sep; 13(9):610-4. PubMed ID: 20799141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The discovery process in the pharmaceutical industry].
    Scatton B
    J Soc Biol; 2009; 203(3):249-69. PubMed ID: 19833071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry.
    Litten RZ; Ryan M; Falk D; Fertig J
    Alcohol Clin Exp Res; 2014 May; 38(5):1196-9. PubMed ID: 24689461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CHI's Fourth Annual Drug Discovery Chemistry Conference. Kinase inhibitor chemistry: charting the chemical space. 7-8 April 2009, San Diego, CA, USA.
    Seneci P
    IDrugs; 2009 Jun; 12(6):358-62. PubMed ID: 19517315
    [No Abstract]   [Full Text] [Related]  

  • 29. The importance of drug-target residence time.
    Zhang R; Monsma F
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):488-96. PubMed ID: 19562645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Productive university, industry, and government relationships in preclinical drug discovery and development: considerations toward a synergistic lingua franca.
    Janero DR
    Expert Opin Drug Discov; 2012 Jun; 7(6):449-56. PubMed ID: 22540843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer drug discovery through collaboration.
    Lengauer C; Diaz LA; Saha S
    Nat Rev Drug Discov; 2005 May; 4(5):375-80. PubMed ID: 15864266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can biochemistry drive drug discovery beyond simple potency measurements?
    Chène P
    Drug Discov Today; 2012 Apr; 17(7-8):388-95. PubMed ID: 22326379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compound scale-up at the discovery-development interface.
    Nikitenko AA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug discovery and the medicinal chemist.
    Maryanoff BE
    Future Med Chem; 2009 Apr; 1(1):11-5. PubMed ID: 21426067
    [No Abstract]   [Full Text] [Related]  

  • 35. Accessing external innovation in drug discovery and development.
    Tufféry P
    Expert Opin Drug Discov; 2015 Jun; 10(6):579-89. PubMed ID: 25910932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Academic drug discovery: current status and prospects.
    Everett JR
    Expert Opin Drug Discov; 2015; 10(9):937-44. PubMed ID: 26088126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticipating drug side effects by comparative pharmacology.
    Garcia-Serna R; Mestres J
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1253-63. PubMed ID: 20662552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling of activity landscapes for drug discovery.
    Bajorath J
    Expert Opin Drug Discov; 2012 Jun; 7(6):463-73. PubMed ID: 22475223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pursuit of personalized anticancer therapy: leveraging collaboration between academia and the biotech/pharmaceutical industry.
    Buck E; Mulvihill M; Iwata KK
    Mt Sinai J Med; 2010; 77(4):358-65. PubMed ID: 20687181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.
    Wetherington JD; Pfister M; Banfield C; Stone JA; Krishna R; Allerheiligen S; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):31S-46S. PubMed ID: 20881215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.